Daratumumab vs QL2109
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Daratumumab
Marketed by Johnson & Johnson
NCT02076009 · Phase 3 · completed
This open-label, randomized Phase 3 trial (POLLUX) assigned 569 patients with relapsed or refractory multiple myeloma to lenalidomide and dexamethasone with or without daratumumab. The primary endpoint was progression-free survival. At the protocol-specified interim analysis, daratumumab significantly lowered the risk of progression or death (hazard ratio 0.37, 95% CI 0.27 to 0.52, P<0.001), so the primary was met. Source: the peer-reviewed paper (Dimopoulos et al., N Engl J Med 2016).
Next expected readout: November 2026 · NCT04973605 (registry estimate)
Reported efficacy
Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8) (met)
Result source: NCT03901963
QL2109
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT07018050 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Daratumumab | QL2109 |
|---|---|---|
| PFS, median | 46.7bNCT0254138315 other results
| —Trial running · NCT06742138 |
| OS, median | 67.6 vs 51.8vs Lenalidomide, Low-dose DexamethasoneNCT0207600913 other results
| —Trial running · NCT06742138 |
| ORR | 43.3% vs 39.4%vs Daratumumab IVNCT0327710528 other results
| —Trial running · NCT06742138 |
| VGPR or better | 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT020760098 other results
| —Trial running · NCT06742138 |
| MRD negativity | 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT036520648 other results
| —Trial running · NCT06742138 |
PFS, median
- Daratumumab
- 46.7bNCT02541383
15 other results
- 36.4 vs 19.3 NCT02195479
- 5.6 vs 6.1 NCT03277105
- 45.3 vs 29.6 NCT02252172
- 52.8 NCT02541383
- 11.8 NCT03450057
- 3.6 NCT01985126
- 5.6 NCT00574288
- 6.2 NCT01592370
- 4.9 NCT01985126
- 2.4 NCT00574288
- 6.9 NCT01592370
- 3.0 NCT01592370
- 81.1 NCT02316106
- 84.4 NCT02316106
- 81.3 NCT02316106
- QL2109
- —Trial running · NCT06742138
OS, median
- Daratumumab
- 67.6 vs 51.8vs Lenalidomide, Low-dose DexamethasoneNCT02076009
13 other results
- 49.6 vs 38.5 NCT02136134
- 90.3 vs 64.1 NCT02252172
- 83.0 vs 53.6 NCT02195479
- 28.2 vs 25.6 NCT03277105
- 50.8 vs 43.6 NCT03158688
- 18.6 NCT01985126
- 34.3 NCT00574288
- 30.4 NCT01592370
- 19.4 NCT01985126
- 18.2 NCT00574288
- 24.5 NCT03450057
- 52.6 NCT01592370
- 14.9 NCT01592370
- QL2109
- —Trial running · NCT06742138
ORR
- Daratumumab
- 43.3% vs 39.4%vs Daratumumab IVNCT03277105
28 other results
- 92.9% vs 76.4% NCT02076009
- 82.9% vs 63.2% NCT02136134
- 92.9% vs 81.6% NCT02252172
- 90.9% vs 73.9% NCT02195479
- 84.3% vs 74.7% NCT03158688
- 91.7% vs 75% NCT02252172
- 29.2% NCT01985126
- 81.3% NCT01615029
- 88.1% NCT03412565
- 90.8% NCT03412565
- 84.8% NCT03412565
- 11.1% NCT01985126
- 0% NCT03000452
- 66.7% NCT01615029
- 75% NCT01615029
- 100% NCT01615029
- 100% NCT01615029
- 35.7% NCT00574288
- 10% NCT00574288
- 56.1% NCT02316106
- 56.1% NCT02316106
- 37.5% NCT02316106
- 97% NCT03412565
- 47.4% NCT03450057
- 66.7% NCT00574288
- 33.3% NCT00574288
- 0% NCT00574288
- 33.3% NCT00574288
- QL2109
- —Trial running · NCT06742138
VGPR or better
- Daratumumab
- 75.8% vs 44.2%vs Lenalidomide, Low-dose DexamethasoneNCT02076009
8 other results
- 59.2% vs 29.1% NCT02136134
- 81.5% vs 56.9% NCT02252172
- 71.1% vs 49.7% NCT02195479
- 23.6% vs 21.6% NCT03277105
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- 77.3% NCT03412565
- QL2109
- —Trial running · NCT06742138
MRD negativity
- Daratumumab
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
8 other results
- 60.9% vs 39.4% NCT03652064
- 18.3% vs 5.2% NCT03158688
- 13.5% vs 2.8% NCT02136134
- 32.1% vs 11.1% NCT02252172
- 28.3% vs 7% NCT02195479
- 25.4% NCT03412565
- 21.5% NCT03412565
- 27.3% NCT03412565
- QL2109
- —Trial running · NCT06742138
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QL2109: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Daratumumab: 4 of 4 rows · QL2109: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Daratumumab |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more resultsn/a: no completion milestone NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3 n/a: no completion milestone NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3 94.9% NCT03901963 · Phase 3 · combination n/a: no completion milestone16 mg/kg NCT01985126 · Phase 2 n/a: no completion milestone8 mg/kg NCT01985126 · Phase 2 66.7%24 mg/kg NCT00574288 · Phase 2 66.7%16 mg/kg NCT00574288 · Phase 2 66.7%16 mg/kg NCT00574288 · Phase 2 100%8 mg/kg NCT00574288 · Phase 2 86.7%8 mg/kg NCT00574288 · Phase 2 100%4 mg/kg NCT00574288 · Phase 2 100%<4 mg/kg NCT00574288 · Phase 2 10% NCT05511428 · Phase 4 · registry result, not featured evidence n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence —Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination —Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02252172 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02195479 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03277105 · Phase 3 · registry result, not featured evidence —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 67.3% NCT03158688 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3 0% NCT01415882 · Phase 2 · registry result, not featured evidence · combination 6.1% NCT03477539 · Phase 2 · registry result, not featured evidence 97.6%Arm A (Long Intense) NCT02316106 · Phase 2 · registry result, not featured evidence 100%Arm B (Intermediate) NCT02316106 · Phase 2 · registry result, not featured evidence 100%Arm C (Short Intense) NCT02316106 · Phase 2 · registry result, not featured evidence 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 77.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · registry result, not featured evidence · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 0% NCT03490344 · Phase 2 · registry result, not featured evidence 15.4% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 60.5% NCT03450057 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT03000452 · Phase 2 · registry result, not featured evidence · combination 0% NCT02944565 · Phase 2 · registry result, not featured evidence 33.3%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 50%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 100%8mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 33.3%4 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 66.7%2 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 83.3%Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 85.7%Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 83.7%Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 72.7%Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 38.5%Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 100%Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 99%Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%1-5 mCi in 50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence 0%1-5 mCi in 20mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence 0%1-5 mCi in 3-50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more results— NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT03901963 · Phase 3 · combination —16 mg/kg NCT01985126 · Phase 2 —8 mg/kg NCT01985126 · Phase 2 33.3%24 mg/kg NCT00574288 · Phase 2 0%16 mg/kg NCT00574288 · Phase 2 0%16 mg/kg NCT00574288 · Phase 2 0%8 mg/kg NCT00574288 · Phase 2 0%8 mg/kg NCT00574288 · Phase 2 0%4 mg/kg NCT00574288 · Phase 2 10%<4 mg/kg NCT00574288 · Phase 2 5% NCT05511428 · Phase 4 · registry result, not featured evidence — NCT03652064 · Phase 3 · registry result, not featured evidence —Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination —Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination — NCT02252172 · Phase 3 · registry result, not featured evidence · combination — NCT02195479 · Phase 3 · registry result, not featured evidence · combination — NCT03277105 · Phase 3 · registry result, not featured evidence —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence — NCT03158688 · Phase 3 · registry result, not featured evidence · combination — NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3 — NCT01415882 · Phase 2 · registry result, not featured evidence · combination — NCT03477539 · Phase 2 · registry result, not featured evidence —Arm A (Long Intense) NCT02316106 · Phase 2 · registry result, not featured evidence —Arm B (Intermediate) NCT02316106 · Phase 2 · registry result, not featured evidence —Arm C (Short Intense) NCT02316106 · Phase 2 · registry result, not featured evidence —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination — NCT03490344 · Phase 2 · registry result, not featured evidence — NCT02874742 · Phase 2 · registry result, not featured evidence · combination — NCT03450057 · Phase 2 · registry result, not featured evidence · combination — NCT03000452 · Phase 2 · registry result, not featured evidence · combination — NCT02944565 · Phase 2 · registry result, not featured evidence 0%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 12.5%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 75%8mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 0%4 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 33.3%2 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy —1-5 mCi in 50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence —1-5 mCi in 20mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence —1-5 mCi in 3-50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 72.4%a NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3 show 54 more results55.1% NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3 29% NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3 30.2% NCT03901963 · Phase 3 · combination 31.1%16 mg/kg NCT01985126 · Phase 2 33.3%8 mg/kg NCT01985126 · Phase 2 66.7%24 mg/kg NCT00574288 · Phase 2 66.7%16 mg/kg NCT00574288 · Phase 2 38.1%16 mg/kg NCT00574288 · Phase 2 33.3%8 mg/kg NCT00574288 · Phase 2 40%8 mg/kg NCT00574288 · Phase 2 0%4 mg/kg NCT00574288 · Phase 2 35%<4 mg/kg NCT00574288 · Phase 2 15% NCT05511428 · Phase 4 · registry result, not featured evidence 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence 42.9%Daratumumab (IV)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination 54.2%Daratumumab (SC)+Pomalidomide+Dexa NCT03180736 · Phase 3 · registry result, not featured evidence · combination 79.4% NCT02252172 · Phase 3 · registry result, not featured evidence · combination 53.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination 31.9% NCT03277105 · Phase 3 · registry result, not featured evidence 49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 68.5% NCT03158688 · Phase 3 · registry result, not featured evidence · combination 33.3% NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3 58.3% NCT01415882 · Phase 2 · registry result, not featured evidence · combination 26.5% NCT03477539 · Phase 2 · registry result, not featured evidence 48.8%Arm A (Long Intense) NCT02316106 · Phase 2 · registry result, not featured evidence 34.1%Arm B (Intermediate) NCT02316106 · Phase 2 · registry result, not featured evidence 10%Arm C (Short Intense) NCT02316106 · Phase 2 · registry result, not featured evidence 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 33.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · registry result, not featured evidence · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 30% NCT03490344 · Phase 2 · registry result, not featured evidence 46.5% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 28.9% NCT03450057 · Phase 2 · registry result, not featured evidence · combination 38.9% NCT03000452 · Phase 2 · registry result, not featured evidence · combination 0% NCT02944565 · Phase 2 · registry result, not featured evidence 66.7%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 68.8%16 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 75%8mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 66.7%4 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 66.7%2 mg/kg NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 50%Nivolumab + Daratumumab Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination —Nivolumab + Daratumumab_Cohort A1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 100%Nivolumab + Daratumumab_Cohort A2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 36.6%Nivolumab + Daratumumab_Cohort B1 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 40.9%Nivolumab + Daratumumab_Cohort B2 NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 60%Nivolumab + Ipilimumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 47.2%Nivolumab + Lirilumab NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination 47.6%Nivolumab Monotherapy (Expansion) NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%1-5 mCi in 50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence 0%1-5 mCi in 20mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence 0%1-5 mCi in 3-50mg of Antibody NCT03665155 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a neutropenia 65.4% diarrhoea 59.7% upper respiratory tract infection 43.5% NCT02076009 · Phase 3 · combination · Multiple Myeloma · phase 3 show 51 more resultsthrombocytopenia 59.7% peripheral sensory neuropathy 50.2% diarrhoea 36.2% NCT02136134 · Phase 3 · combination · Multiple Myeloma · phase 3 fatigue 34.2% (placebo 13.3%) upper respiratory tract infection 30.1% (placebo 7.7%) arthralgia 26.9% (placebo 17.9%) NCT03301220 · Phase 3 · combination · Multiple Myeloma · phase 3 16 mg/kg confusional state 33.3% cytokine release syndrome 33.3% eczema asteatotic 33.3% NCT00574288 · Phase 2 diarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence fatigue 57.1% neutropenia 57.1% lymphopenia 42.9% NCT03180736 · Phase 3 · registry result, not featured evidence · combination neutropenia 72.5% anaemia 38.7% thrombocytopenia 33.8% NCT03180736 · Phase 3 · registry result, not featured evidence · combination diarrhoea 65.1% neutropenia 61.5% fatigue 44.8% NCT02252172 · Phase 3 · registry result, not featured evidence · combination neutropenia 50.3% thrombocytopenia 49.7% anaemia 31.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination anaemia 27.3% neutropenia 20% thrombocytopenia 18.8% NCT03277105 · Phase 3 · registry result, not featured evidence peripheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence thrombocytopenia 38.6% anaemia 36.7% hypertension 36.7% NCT03158688 · Phase 3 · registry result, not featured evidence · combination neutropenia 44.4% anaemia 33.3% fatigue 33.3% NCT03357952 · Phase 2/3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 2/3 anemia 91.7% fatigue 91.7% lymphocyte count decreased 91.7% NCT01415882 · Phase 2 · registry result, not featured evidence · combination platelet count decreased 93.9% anemia 91.8% neutrophil count decreased 83.7% NCT03477539 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 48.8% fatigue 46.3% cough 43.9% NCT02316106 · Phase 2 · registry result, not featured evidence fatigue 61% arthralgia 46.3% cough 36.6% NCT02316106 · Phase 2 · registry result, not featured evidence headache 32.5% cough 27.5% fatigue 22.5% NCT02316106 · Phase 2 · registry result, not featured evidence thrombocytopenia 56.7% anaemia 44.8% constipation 44.8% NCT03412565 · Phase 2 · registry result, not featured evidence · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · registry result, not featured evidence · combination thrombocytopenia 51.5% anaemia 37.9% hypertension 34.8% NCT03412565 · Phase 2 · registry result, not featured evidence · combination neutropenia 67.7% diarrhoea 49.2% anaemia 40% NCT03412565 · Phase 2 · registry result, not featured evidence · combination fatigue 71.7% upper respiratory tract infection 67.7% diarrhoea 65.7% NCT02874742 · Phase 2 · registry result, not featured evidence · combination anaemia 28.9% fatigue 23.7% hypocalcaemia 18.4% NCT03450057 · Phase 2 · registry result, not featured evidence · combination anaemia 66.7% fatigue 50% thrombocytopenia 38.9% NCT03000452 · Phase 2 · registry result, not featured evidence · combination 16 mg/kg muscle spasms 100% oedema peripheral 100% bronchitis 66.7% NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 16 mg/kg neutropenia 90.6% diarrhoea 56.3% cough 50% NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 8mg/kg fatigue 100% neutropenia 100% diarrhoea 75% NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 4 mg/kg cataract 100% constipation 100% diarrhoea 100% NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination 2 mg/kg constipation 100% fatigue 100% neutropenia 100% NCT01615029 · Phase 1/2 · registry result, not featured evidence · combination anaemia 50% arthralgia 50% cough 50% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 80% diarrhoea 80% hypomagnesaemia 80% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 24.4% infusion related reaction 24.4% neutropenia 22% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination anaemia 18.2% diarrhoea 18.2% infusion related reaction 18.2% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 46.2% pyrexia 38.5% cough 33.8% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 41.7% diarrhoea 29.2% anaemia 25% NCT01592370 · Phase 1/2 · registry result, not featured evidence · combination fatigue 43.8% cough 27.6% diarrhoea 26.7% NCT01592370 · Phase 1/2 · registry result, not featured evidence · monotherapy 1-5 mCi in 50mg of Antibody lymphocyte count decreased 66.7% neutrophil count decreased 66.7% white blood cell decreased 66.7% NCT03665155 · Phase 1/2 · registry result, not featured evidence 1-5 mCi in 20mg of Antibody lymphocyte count decreased 57.1% neutrophil count decreased 28.6% white blood cell decreased 28.6% NCT03665155 · Phase 1/2 · registry result, not featured evidence 1-5 mCi in 3-50mg of Antibody anemia 0% aspartate aminotransferase increased 0% blood bilirubin increased 0% NCT03665155 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 51 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Daratumumab
show 8 more results
show 5 more results
show 4 more results
show 6 more results
show 6 more results
show 4 more results
show 5 more results
show 5 more results
show 21 more results
show 12 more results
show 12 more results
+ 109 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daratumumab's landscape · QL2109's landscape